NasdaqGM:GNMK

Stock Analysis Report

Executive Summary

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has GenMark Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.9%

NasdaqGM:GNMK

-1.6%

US Medical Equipment

-1.6%

US Market


1 Year Return

-19.8%

NasdaqGM:GNMK

10.2%

US Medical Equipment

-3.0%

US Market

GNMK underperformed the Medical Equipment industry which returned 10.2% over the past year.

GNMK underperformed the Market in United States of America which returned -3% over the past year.


Share holder returns

GNMKIndustryMarket
7 Day-5.9%-1.6%-1.6%
30 Day-3.8%-2.6%-5.7%
90 Day-8.4%7.4%0.2%
1 Year-19.8%-19.8%11.1%10.2%-0.8%-3.0%
3 Year-30.2%-30.2%65.1%60.0%38.1%29.1%
5 Year-43.2%-43.2%127.0%101.0%50.8%34.1%

Price Volatility Vs. Market

How volatile is GenMark Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is GenMark Diagnostics undervalued based on future cash flows and its price relative to the stock market?

23.74x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

GenMark Diagnostics's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

GenMark Diagnostics's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

GenMark Diagnostics is loss making, we can't compare its value to the US Medical Equipment industry average.

GenMark Diagnostics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for GenMark Diagnostics, we can't assess if its growth is good value.


Price Based on Value of Assets

GenMark Diagnostics is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is GenMark Diagnostics expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

59.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

GenMark Diagnostics's revenue is expected to grow significantly at over 20% yearly.

GenMark Diagnostics's earnings are expected to grow significantly at over 20% yearly.

GenMark Diagnostics's revenue growth is expected to exceed the United States of America market average.

GenMark Diagnostics's earnings growth is expected to exceed the United States of America market average.

GenMark Diagnostics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if GenMark Diagnostics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has GenMark Diagnostics performed over the past 5 years?

-7.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

GenMark Diagnostics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare GenMark Diagnostics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare GenMark Diagnostics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if GenMark Diagnostics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if GenMark Diagnostics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if GenMark Diagnostics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is GenMark Diagnostics's financial position?


Financial Position Analysis

GenMark Diagnostics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

GenMark Diagnostics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

GenMark Diagnostics's level of debt (326.6%) compared to net worth is high (greater than 40%).

Unable to establish if GenMark Diagnostics's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

GenMark Diagnostics has sufficient cash runway for 1.2 years based on current free cash flow.

GenMark Diagnostics has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -6.2% each year.


Next Steps

Dividend

What is GenMark Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate GenMark Diagnostics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate GenMark Diagnostics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as GenMark Diagnostics has not reported any payouts.

Unable to verify if GenMark Diagnostics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as GenMark Diagnostics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of GenMark Diagnostics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of GenMark Diagnostics's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Hany Massarany (58yo)

8.3yrs

Tenure

US$3,344,692

Compensation

Mr. Hany Massarany has been the Chief Executive Officer of GenMark Diagnostics, Inc. since joined it in May 1, 2011 and has been its President since May 2011 Mr. Massarany served as the Chief Operating Off ...


CEO Compensation Analysis

Hany's remuneration is higher than average for companies of similar size in United States of America.

Hany's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.8yrs

Average Tenure

44yo

Average Age

The tenure for the GenMark Diagnostics management team is about average.


Board Age and Tenure

6.6yrs

Average Tenure

61.5yo

Average Age

The tenure for the GenMark Diagnostics board of directors is about average.


Insider Trading

GenMark Diagnostics individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$11,38121 Aug 19
Michael Gleeson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Corporate & Strategic Accounts
Shares1,821
Max PriceUS$6.25
SellUS$3,18821 Aug 19
John Ek
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares510
Max PriceUS$6.25
SellUS$50,50021 Aug 19
Hany Massarany
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares8,080
Max PriceUS$6.25
SellUS$2,84921 Aug 19
Brian Mitchell
EntityIndividual
Role
Senior Key Executive
Senior VP of Operations
Shares435
Max PriceUS$6.55
SellUS$12,29421 Aug 19
Scott Mendel
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares1,967
Max PriceUS$6.25
SellUS$10,64421 Aug 19
Eric Stier
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares1,703
Max PriceUS$6.25
SellUS$1,99421 Aug 19
Tyler Jensen
EntityIndividual
Shares319
Max PriceUS$6.25
SellUS$5,90508 Aug 19
James McNally
EntityIndividual
Role
Head of Marketing
Senior VP of Marketing & Business Development
Shares1,006
Max PriceUS$5.87
SellUS$4,17408 Aug 19
Brian Mitchell
EntityIndividual
Role
Senior Key Executive
Senior VP of Operations
Shares711
Max PriceUS$5.87
SellUS$11,09408 Aug 19
John Ek
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,890
Max PriceUS$5.87
SellUS$6,09831 May 19
John Ek
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares924
Max PriceUS$6.60
SellUS$10,32231 May 19
Eric Stier
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares1,564
Max PriceUS$6.60
SellUS$11,41131 May 19
Michael Gleeson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Corporate & Strategic Accounts
Shares1,729
Max PriceUS$6.60
SellUS$13,57631 May 19
James McNally
EntityIndividual
Role
Head of Marketing
Senior VP of Marketing & Business Development
Shares2,057
Max PriceUS$6.60
SellUS$11,41131 May 19
Brian Mitchell
EntityIndividual
Role
Senior Key Executive
Senior VP of Operations
Shares1,729
Max PriceUS$6.60
SellUS$15,20631 May 19
Scott Mendel
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares2,304
Max PriceUS$6.60
SellUS$68,43531 May 19
Hany Massarany
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares10,369
Max PriceUS$6.60
SellUS$5,44531 May 19
Tyler Jensen
EntityIndividual
Shares825
Max PriceUS$6.60
SellUS$1,52928 May 19
James McNally
EntityIndividual
Role
Head of Marketing
Senior VP of Marketing & Business Development
Shares231
Max PriceUS$6.62
SellUS$41,35528 May 19
Hany Massarany
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares6,247
Max PriceUS$6.62
SellUS$1,52928 May 19
Brian Mitchell
EntityIndividual
Role
Senior Key Executive
Senior VP of Operations
Shares231
Max PriceUS$6.62
SellUS$6,52728 May 19
Eric Stier
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares986
Max PriceUS$6.62
SellUS$9,07628 May 19
Scott Mendel
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares1,371
Max PriceUS$6.62
SellUS$6,81228 May 19
Michael Gleeson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Corporate & Strategic Accounts
Shares1,029
Max PriceUS$6.62
SellUS$2,14424 May 19
Tyler Jensen
EntityIndividual
Shares313
Max PriceUS$6.85
SellUS$3,43224 May 19
John Ek
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares501
Max PriceUS$6.85
SellUS$13,02522 May 19
Scott Mendel
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares1,907
Max PriceUS$6.83
SellUS$3,38122 May 19
John Ek
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares495
Max PriceUS$6.83
SellUS$53,52722 May 19
Hany Massarany
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares7,837
Max PriceUS$6.83
SellUS$12,06222 May 19
Michael Gleeson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Corporate & Strategic Accounts
Shares1,766
Max PriceUS$6.83
SellUS$2,11022 May 19
Tyler Jensen
EntityIndividual
Shares309
Max PriceUS$6.83
SellUS$11,28322 May 19
Eric Stier
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares1,652
Max PriceUS$6.83
SellUS$3,14020 May 19
Brian Mitchell
EntityIndividual
Role
Senior Key Executive
Senior VP of Operations
Shares448
Max PriceUS$7.01
SellUS$5,09506 May 19
Brian Mitchell
EntityIndividual
Role
Senior Key Executive
Senior VP of Operations
Shares654
Max PriceUS$7.79
SellUS$7,22906 May 19
James McNally
EntityIndividual
Role
Head of Marketing
Senior VP of Marketing & Business Development
Shares928
Max PriceUS$7.79
SellUS$357,32201 Mar 19
Michael Gleeson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Corporate & Strategic Accounts
Shares45,168
Max PriceUS$7.96
SellUS$76,45227 Feb 19
Eric Stier
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares11,243
Max PriceUS$6.80
SellUS$370,70727 Feb 19
Hany Massarany
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares54,596
Max PriceUS$6.79
SellUS$35,34227 Feb 19
John Ek
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares5,205
Max PriceUS$6.79
SellUS$74,66327 Feb 19
Brian Mitchell
EntityIndividual
Role
Senior Key Executive
Senior VP of Operations
Shares10,996
Max PriceUS$6.79
SellUS$77,58827 Feb 19
Scott Mendel
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares11,410
Max PriceUS$6.80
SellUS$83,49727 Feb 19
James McNally
EntityIndividual
Role
Head of Marketing
Senior VP of Marketing & Business Development
Shares12,297
Max PriceUS$6.79
SellUS$82,13927 Feb 19
Michael Gleeson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Corporate & Strategic Accounts
Shares12,097
Max PriceUS$6.79
SellUS$3,66522 Feb 19
John Ek
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares595
Max PriceUS$6.16
SellUS$12,70822 Feb 19
Scott Mendel
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares2,063
Max PriceUS$6.16
SellUS$3,28022 Feb 19
Brian Mitchell
EntityIndividual
Role
Senior Key Executive
Senior VP of Operations
Shares519
Max PriceUS$6.32
SellUS$12,23422 Feb 19
Eric Stier
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares1,986
Max PriceUS$6.16
SellUS$13,06522 Feb 19
Michael Gleeson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Corporate & Strategic Accounts
Shares2,121
Max PriceUS$6.16
SellUS$34,26222 Feb 19
Hany Massarany
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares5,562
Max PriceUS$6.16
SellUS$21,21625 Jan 19
Eric Stier
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares3,596
Max PriceUS$5.90
SellUS$27,90725 Jan 19
James McNally
EntityIndividual
Role
Head of Marketing
Senior VP of Marketing & Business Development
Shares4,730
Max PriceUS$5.90
SellUS$89,47925 Jan 19
Hany Massarany
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares15,166
Max PriceUS$5.90
SellUS$23,44725 Jan 19
Michael Gleeson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Corporate & Strategic Accounts
Shares3,974
Max PriceUS$5.90
SellUS$23,44725 Jan 19
Brian Mitchell
EntityIndividual
Role
Senior Key Executive
Senior VP of Operations
Shares3,974
Max PriceUS$5.90
SellUS$31,25225 Jan 19
Scott Mendel
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares5,297
Max PriceUS$5.90
SellUS$4,92829 Nov 18
Michael Gleeson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Corporate & Strategic Accounts
Shares970
Max PriceUS$5.08
SellUS$4,72429 Nov 18
Eric Stier
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares930
Max PriceUS$5.08
SellUS$29,89129 Nov 18
Hany Massarany
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares5,884
Max PriceUS$5.08
SellUS$1,11329 Nov 18
Brian Mitchell
EntityIndividual
Role
Senior Key Executive
Senior VP of Operations
Shares219
Max PriceUS$5.08
SellUS$6,56329 Nov 18
Scott Mendel
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares1,292
Max PriceUS$5.08
SellUS$1,11329 Nov 18
James McNally
EntityIndividual
Role
Head of Marketing
Senior VP of Marketing & Business Development
Shares219
Max PriceUS$5.08
SellUS$8,78026 Nov 18
Michael Gleeson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Corporate & Strategic Accounts
Shares1,814
Max PriceUS$4.84
SellUS$8,21326 Nov 18
Eric Stier
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares1,697
Max PriceUS$4.84
SellUS$38,94726 Nov 18
Hany Massarany
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares8,047
Max PriceUS$4.84
SellUS$9,48226 Nov 18
Scott Mendel
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares1,959
Max PriceUS$4.84
SellUS$2,08620 Nov 18
Brian Mitchell
EntityIndividual
Role
Senior Key Executive
Senior VP of Operations
Shares418
Max PriceUS$4.99
SellUS$7,57106 Nov 18
Hany Massarany
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares1,561
Max PriceUS$4.85
SellUS$1,69806 Nov 18
Eric Stier
EntityIndividual
Role
Chief Legal Officer
Senior VP
Shares350
Max PriceUS$4.85
SellUS$1,85306 Nov 18
Michael Gleeson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Corporate & Strategic Accounts
Shares382
Max PriceUS$4.85
SellUS$3,31306 Nov 18
Brian Mitchell
EntityIndividual
Role
Senior Key Executive
Senior VP of Operations
Shares683
Max PriceUS$4.85
SellUS$1,09606 Nov 18
Scott Mendel
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares226
Max PriceUS$4.85
SellUS$7,97306 Nov 18
James McNally
EntityIndividual
Role
Head of Marketing
Senior VP of Marketing & Business Development
Shares1,644
Max PriceUS$4.85

Ownership Breakdown


Management Team

  • Hany Massarany (58yo)

    CEO, President & Director

    • Tenure: 8.3yrs
    • Compensation: US$3.34m
  • Brian Mitchell (54yo)

    Senior VP of Operations

    • Tenure: 0.0yrs
    • Compensation: US$943.18k
  • Mike Gleeson (44yo)

    Senior Vice President of Corporate & Strategic Accounts

    • Tenure: 5.4yrs
    • Compensation: US$967.56k
  • Scott Mendel (52yo)

    Chief Operating Officer

    • Tenure: 0.5yrs
    • Compensation: US$1.28m
  • Eric Stier (43yo)

    Senior VP

    • Tenure: 6.3yrs
    • Compensation: US$829.12k
  • James McNally (39yo)

    Senior VP of Marketing & Business Development

    • Tenure: 2.8yrs
    • Compensation: US$1.18m
  • Mike Harkins

    Senior Vice President of Sales

    • Tenure: 0.3yrs
  • Johnny Ek (43yo)

    Chief Financial Officer

    • Tenure: 0.5yrs

Board Members

  • Daryl Faulkner (70yo)

    Non-Executive Director

    • Tenure: 9.4yrs
    • Compensation: US$156.00k
  • Hany Massarany (58yo)

    CEO, President & Director

    • Tenure: 8.3yrs
    • Compensation: US$3.34m
  • Michael Kagnoff (50yo)

    Non-Executive Director

    • Tenure: 4.5yrs
    • Compensation: US$145.00k
  • Jim Fox (67yo)

    Chairman of the Board

    • Tenure: 5.0yrs
    • Compensation: US$237.98k
  • Kevin O'Boyle (63yo)

    Non-Executive Director

    • Tenure: 9.4yrs
    • Compensation: US$166.00k
  • Lisa Giles (60yo)

    Non-Executive Director

    • Tenure: 4.5yrs
    • Compensation: US$150.00k

Company Information

GenMark Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GenMark Diagnostics, Inc.
  • Ticker: GNMK
  • Exchange: NasdaqGM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$350.954m
  • Shares outstanding: 57.44m
  • Website: https://www.genmarkdx.com

Number of Employees


Location

  • GenMark Diagnostics, Inc.
  • 5964 La Place Court
  • Carlsbad
  • California
  • 92008
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNMKNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2010
GNFDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2010
0IUTLSE (London Stock Exchange)YesCommon StockGBUSDMay 2010

Biography

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/25 00:25
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.